Beam Therapeutics Inc.
25.175USD
-1.6550 (-6.17%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 60.9M | 377.7M | 63.5M | 139.7M | 48.6M | 62.7M |
| Q1 | 8.4M | 24.2M | 7.4M | 7.5M | 31.7M | — |
| Q2 | 16.7M | 20.1M | 11.8M | 8.5M | 490.0K | — |
| Q3 | 15.8M | 17.2M | 14.3M | 9.7M | 10.0M | — |
| Q4 | 20.0M* | 316.2M* | 30.1M* | 114.1M* | 11.6M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -4.13 | -1.72 | -4.58 | -.810 | -4.45 | -4.74 |
| Q1 | -1.01 | -1.33 | -1.21 | -1.23 | -.910 | — |
| Q2 | -1.02 | -1.08 | -1.11 | -1.00 | -1.18 | — |
| Q3 | -1.56 | -1.22 | -1.17 | -1.10 | -1.17 | — |
| Q4 | -.548* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| 1.85* |
| -1.10* |
| 2.47* |
| -1.19 |
| — |